Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 13 Feb 23 424B4 Prospectus supplement with pricing info
- 10 Feb 23 EFFECT Notice of effectiveness
- 20 Jan 23 S-1/A IPO registration (amended)
- 4 Nov 22 S-1/A IPO registration (amended)
-
7 Oct 22 S-1/A IPO registration (amended)
- 13 May 22 S-1/A IPO registration (amended)
- 10 May 22 S-1/A IPO registration (amended)
- 29 Apr 22 S-1 IPO registration
BLAC similar filings
Filing view
External links
EXHIBIT 99.3
Consent to be Named as a Director Nominee
In connection with the filing by Bellevue Life Sciences Acquisition Corp. (the “Company”) of the Registration Statement on Form S-1 with the US Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the Board of Directors of the Company in the Registration Statement and any and all amendments and supplements thereto.
I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
/s/ Steven Reed |
Steven Reed |
Dated: October 6, 2022